Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer.
OBJECTIVE
Pigment epithelium-derived factor (PEDF) plays a protective role against oxidative stress. Levels of circulating PEDF have not been examined in patients with prostate cancer. We examined whether PEDF can be used to predict the clinical features of prostate cancer prior to therapy.


METHODS
Two hundred patients with an abnormal serum level of prostate-specific antigen (PSA) who underwent biopsy between 2008 and 2011 were identified for retrospective analysis. We determined the relationship of the PEDF level to clinical parameters of prostate cancer. We measured levels of PEDF and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in all 200 patients, 100 of whom had histologically-confirmed prostate cancer at the outset. We also investigated the PEDF expression in prostate cancer tissues by immunohistochemistry.


RESULTS
The PEDF level was significantly higher in patients with prostate cancer than in those without. Statistical analysis confirmed that PEDF was significant, positively associated with pathological grading (Gleason score). However, PEDF expression was only detected in few prostate cancer cells by immunohistochemistry. Levels of the oxidative marker, 8-OHdG, in patients with prostate cancer are higher than in those without cancer.


CONCLUSIONS
Preoperative PEDF measurement in patients with prostate cancer may provide clinically relevant information regarding the pathological grade of tumor.
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan ihisamit@med.teikyo-u.ac.jp.
Hisamitsu
H
Ide
Department of Pathophysiology and Therapeutics of Diabetic, Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
Sho-Ichi
S
Yamagishi
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Yan
Y
Lu
Department of Biostatistics and Epidemiology, Yokohama City University School of Medicine, Yokohama, Japan.
Kentaro
K
Sakamaki
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Akiko
A
Nakajima
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Akira
A
Horiuchi
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Kosuke
K
Kitamura
Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Schin-Ichi
S
Hisasue
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Satoru
S
Muto
Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Raizo
R
Yamaguchi
Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan.
Shigeo
S
Horie
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005136:Eye Proteins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009414:Nerve Growth Factors / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*; D012189:Retrospective Studies; D015843:Serpins / Q000097:blood*; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D015843:Serpins; D000099174:Pigment Epithelium-Derived Factor
Gleason score; PEDF; Prostate cancer